• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Axsome Therapeutics Inc.

    2/14/23 10:07:26 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email
    SC 13G 1 p23-0588sc13g.htm AXSOME THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Axsome Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    05464T104

    (CUSIP Number)
     

    December 31, 2022

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 05464T10413GPage 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,980,482 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,980,482 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,980,482 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.9%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 05464T10413GPage 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    2,980,482 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    2,980,482 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,980,482 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.9%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 05464T10413GPage 4 of 8 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Axsome Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 22 Cortlandt Street, 16th Floor, New York, New York 10007.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i)

    RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and

     

      (ii) Mr. Roderick Wong ("Mr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:
       
      RTW Investments is a Delaware limited partnership.  Mr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Shares").

     

    Item 2(e). CUSIP NUMBER:
       
      05464T104

     

     

    CUSIP No. 05464T10413GPage 5 of 8 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: _____________________

     

    Item 4. OWNERSHIP.
         
        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
         
        The percentages set forth herein are calculated based upon 43,426,162 Shares outstanding as of October 31, 2022, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 with the Securities and Exchange Commission on November 7, 2022.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    CUSIP No. 05464T10413GPage 6 of 8 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 05464T10413GPage 7 of 8 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: February 14, 2023

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

     

     

    CUSIP No. 05464T10413GPage 8 of 8 Pages

    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATE: February 14, 2023

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong  
    Name: Roderick Wong  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong  
    RODERICK WONG  
         

     

     

    Get the next $AXSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    9/3/2024$140.00Overweight
    Wells Fargo
    8/6/2024$95.00 → $106.00Neutral → Buy
    BofA Securities
    7/22/2024$130.00Buy
    Needham
    4/29/2024$90.00 → $115.00Equal-Weight → Overweight
    Morgan Stanley
    3/19/2024$108.00Outperform
    Robert W. Baird
    More analyst ratings

    $AXSM
    Leadership Updates

    Live Leadership Updates

    See more
    • Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

      11/28/23 6:51:20 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

      NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

      10/11/23 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

      5/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

      NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month. On May 1, as part of Mental Health America's "Light Up Green" initiative, Axsome's New York City headquarters, the One World Trade Center building, will be lit in green, the color for mental health awareness, and through the building's Spireworks program. "Mental Health America's 2024 data co

      5/1/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Participate in Upcoming Investor Conferences

      NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming investor conferences in May: The Citizens 2025 Life Sciences ConferenceThe Company will present on Wednesday, May 7, 2025, at 1:30 p.m. ET in New York, NY BofA Securities 2025 Health Care ConferenceThe Company will present on Tuesday, May 13, 2025, at 3:00 p.m. PT in Las Vegas, NV 2025 RBC Capital Markets Global Healthcare ConferenceThe Company will present on Tuesday, May 20, 2025, at 3:05 p.m. ET in New York, NY Mizuho Neu

      4/22/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mahony Susan

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 8:02:19 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Jeffs Roger

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 8:00:39 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Saad Mark E

      4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

      2/25/25 7:59:08 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

      Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      8/19/22 12:36:14 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Axsome Therapeutics with a new price target

      Jefferies initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $200.00

      4/7/25 8:43:21 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Axsome Therapeutics with a new price target

      Deutsche Bank initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $176.00

      2/11/25 7:01:14 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho reiterated coverage on Axsome Therapeutics with a new price target

      Mizuho reiterated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $122.00 from $124.00 previously

      12/31/24 7:54:59 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Financials

    Live finance-specific insights

    See more
    • Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

      5/5/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2025 on Monday, May 5, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentation

      4/8/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth Auvelity® 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively, representing 89% and 124% year-over-year growth Sunosi® 4Q and full year 2024 net product revenue of $26.2 million and $94.3 million, respectively, representing 16% and 26% year-over-year growth Symbravo® approved in the U.S. for the acute treatment of migraine with or without aura in adults Successful completion of Phase 3 clinical program of AXS-05 in Alzh

      2/18/25 7:00:00 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 3:46:49 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/14/24 7:26:39 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

      SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

      2/13/24 4:58:57 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AXSM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Axsome Therapeutics Inc.

      10-Q - Axsome Therapeutics, Inc. (0001579428) (Filer)

      5/5/25 4:47:38 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Axsome Therapeutics, Inc. (0001579428) (Filer)

      5/5/25 7:33:06 AM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Axsome Therapeutics Inc.

      DEFA14A - Axsome Therapeutics, Inc. (0001579428) (Filer)

      4/25/25 4:32:39 PM ET
      $AXSM
      Biotechnology: Pharmaceutical Preparations
      Health Care